Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
1.210
-0.020 (-1.63%)
At close: Aug 12, 2026, 4:00 PM EDT
1.210
0.00 (0.00%)
After-hours: Aug 12, 2026, 6:36 PM EDT
Sunshine Biopharma Revenue
Sunshine Biopharma had revenue of $8.09M in the quarter ending March 31, 2026, a decrease of -9.13%. This brings the company's revenue in the last twelve months to $35.49M, up 298.74% year-over-year. In the year 2025, Sunshine Biopharma had annual revenue of $36.31M with 4.11% growth.
Revenue (ttm)
$35.49M
Revenue Growth
+298.74%
P/S Ratio
0.07
Revenue / Employee
$709,866
Employees
50
Market Cap
2.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.31M | 1.43M | 4.11% |
| Dec 31, 2024 | 34.87M | 10.78M | 44.75% |
| Dec 31, 2023 | 24.09M | 19.75M | 454.42% |
| Dec 31, 2022 | 4.35M | 4.12M | 1,802.41% |
| Dec 31, 2021 | 228.43K | 157.02K | 219.88% |
| Dec 31, 2020 | 71.41K | 50.29K | 238.10% |
| Dec 31, 2019 | 21.12K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 1.71K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Jul 31, 2009 | - | - | - |
| Jul 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sonoma Pharmaceuticals | 21.92M |
| cbdMD | 19.98M |
| Universe Pharmaceuticals INC | 17.74M |
| InMed Pharmaceuticals | 4.94M |
| China SXT Pharmaceuticals | 1.14M |
| Gelteq | 314.70K |
| RedHill Biopharma | 286.00K |
| Akanda | 258.08K |
SBFM News
- 5 days ago - Sunshine Biopharma launches generic amoxicillin formulation in Canada - TheFly
- 5 days ago - Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market - Accesswire
- 8 days ago - Sunshine announces approval of generic Dienogest tablets for Canadian market - TheFly
- 8 days ago - Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval - Accesswire
- 15 days ago - Sunshine Biopharma announces approval of generic Ondansetron tablets - TheFly
- 15 days ago - Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting - Accesswire
- 23 days ago - Sunshine Biopharma announces publication of new results on MR1-114 - TheFly
- 23 days ago - Sunshine Biopharma and University of Arizona Publish Significant New Research Findings - Accesswire